These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 24095090)

  • 1. Novel bis-ortho-alkoxy-para-piperazinesubstituted-2,4-dianilinopyrimidines (KRCA-0008) as potent and selective ALK inhibitors for anticancer treatment.
    Park CH; Choe H; Jang IY; Kwon SY; Latif M; Lee HK; Lee HJ; Yang EH; Yun JI; Chae CH; Cho SY; Choi SU; Ha JD; Jung H; Kim HR; Kim P; Lee CO; Yun CS; Lee K
    Bioorg Med Chem Lett; 2013 Nov; 23(22):6192-6. PubMed ID: 24095090
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ALK inhibitors of bis-ortho-alkoxy-para-piperazinesubstituted-pyrimidines and -triazines for cancer treatment.
    Lee HJ; Latif M; Choe H; Ali I; Lee HK; Yang EH; Yun JI; Chae CH; Jung JK; Kim HR; Lee CO; Park CH; Lee K
    Arch Pharm Res; 2014; 37(9):1130-8. PubMed ID: 24446111
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of potent ALK inhibitor and its molecular inhibitory mechanism against NSCLC harboring EML4-ALK proteins.
    Kang CH; Yun JI; Lee K; Lee CO; Lee HK; Yun CS; Hwang JY; Cho SY; Jung H; Kim P; Ha JD; Jeon JH; Choi SU; Jeong HG; Kim HR; Park CH
    Biochem Biophys Res Commun; 2015 Aug; 464(3):762-7. PubMed ID: 26168728
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Minor modifications to ceritinib enhance anti-tumor activity in EML4-ALK positive cancer.
    Kang CH; Kim EY; Kim HR; Lee CO; Lee HK; Jeong HG; Choi SU; Yun CS; Hwang JY; Lee JY; Son YH; Ahn S; Lee BH; Jung H; Park CH
    Cancer Lett; 2016 May; 374(2):272-8. PubMed ID: 26923554
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis and evaluation of novel 2,4-diaminopyrimidines bearing bicyclic aminobenzazepines for anaplastic lymphoma kinase (ALK) inhibitor.
    Kang GA; Lee M; Song D; Lee HK; Ahn S; Park CH; Lee CO; Yun CS; Jung H; Kim P; Ha JD; Cho SY; Kim HR; Hwang JY
    Bioorg Med Chem Lett; 2015 Sep; 25(18):3992-8. PubMed ID: 26235945
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanistic understanding of translational pharmacokinetic-pharmacodynamic relationships in nonclinical tumor models: a case study of orally available novel inhibitors of anaplastic lymphoma kinase.
    Yamazaki S; Lam JL; Zou HY; Wang H; Smeal T; Vicini P
    Drug Metab Dispos; 2015 Jan; 43(1):54-62. PubMed ID: 25349124
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic/pharmacodynamic modeling of crizotinib for anaplastic lymphoma kinase inhibition and antitumor efficacy in human tumor xenograft mouse models.
    Yamazaki S; Vicini P; Shen Z; Zou HY; Lee J; Li Q; Christensen JG; Smith BJ; Shetty B
    J Pharmacol Exp Ther; 2012 Mar; 340(3):549-57. PubMed ID: 22129595
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Crizotinib, a small-molecule dual inhibitor of the c-Met and ALK receptor tyrosine kinases.
    Rodig SJ; Shapiro GI
    Curr Opin Investig Drugs; 2010 Dec; 11(12):1477-90. PubMed ID: 21154129
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selective ALK inhibitor alectinib with potent antitumor activity in models of crizotinib resistance.
    Kodama T; Tsukaguchi T; Yoshida M; Kondoh O; Sakamoto H
    Cancer Lett; 2014 Sep; 351(2):215-21. PubMed ID: 24887559
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design and synthesis of novel 3-sulfonylpyrazol-4-amino pyrimidines as potent anaplastic lymphoma kinase (ALK) inhibitors.
    Zhang P; Dong J; Zhong B; Zhang D; Yuan H; Jin C; Xu X; Li H; Zhou Y; Liang Z; Ji M; Xu T; Song G; Zhang L; Chen G; Meng X; Sun D; Shih J; Zhang R; Hou G; Wang C; Jin Y; Yang Q
    Bioorg Med Chem Lett; 2016 Apr; 26(8):1910-8. PubMed ID: 26979157
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CEP-28122, a highly potent and selective orally active inhibitor of anaplastic lymphoma kinase with antitumor activity in experimental models of human cancers.
    Cheng M; Quail MR; Gingrich DE; Ott GR; Lu L; Wan W; Albom MS; Angeles TS; Aimone LD; Cristofani F; Machiorlatti R; Abele C; Ator MA; Dorsey BD; Inghirami G; Ruggeri BA
    Mol Cancer Ther; 2012 Mar; 11(3):670-9. PubMed ID: 22203728
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Crizotinib: a new treatment option for ALK-positive non-small cell lung cancer.
    O'Bryant CL; Wenger SD; Kim M; Thompson LA
    Ann Pharmacother; 2013 Feb; 47(2):189-97. PubMed ID: 23386065
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of 2-arylamino-4-(1-methyl-3-isopropylsulfonyl-4-pyrazol-amino)pyrimidines as potent anaplastic lymphoma kinase (ALK) inhibitors.
    Zhang P; Dong J; Zhong B; Zhang D; Jin C; Meng X; Sun D; Xu X; Zhou Y; Liang Z; Ji M; Li H; Xu T; Song G; Zhang L; Chen G; Yuan H; Shih J; Zhang R; Hou G; Jin Y; Yang Q
    Bioorg Med Chem Lett; 2015 Sep; 25(17):3738-43. PubMed ID: 26130408
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel 2,3,4,5-tetrahydro-benzo[d]azepine derivatives of 2,4-diaminopyrimidine, selective and orally bioavailable ALK inhibitors with antitumor efficacy in ALCL mouse models.
    Mesaros EF; Burke JP; Parrish JD; Dugan BJ; Anzalone AV; Angeles TS; Albom MS; Aimone LD; Quail MR; Wan W; Lu L; Huang Z; Ator MA; Ruggeri BA; Cheng M; Ott GR; Dorsey BD
    Bioorg Med Chem Lett; 2011 Jan; 21(1):463-6. PubMed ID: 21074994
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Crizotinib-resistant NPM-ALK mutants confer differential sensitivity to unrelated Alk inhibitors.
    Ceccon M; Mologni L; Bisson W; Scapozza L; Gambacorti-Passerini C
    Mol Cancer Res; 2013 Feb; 11(2):122-32. PubMed ID: 23239810
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Paracrine receptor activation by microenvironment triggers bypass survival signals and ALK inhibitor resistance in EML4-ALK lung cancer cells.
    Yamada T; Takeuchi S; Nakade J; Kita K; Nakagawa T; Nanjo S; Nakamura T; Matsumoto K; Soda M; Mano H; Uenaka T; Yano S
    Clin Cancer Res; 2012 Jul; 18(13):3592-602. PubMed ID: 22553343
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of an orally efficacious inhibitor of anaplastic lymphoma kinase.
    Gingrich DE; Lisko JG; Curry MA; Cheng M; Quail M; Lu L; Wan W; Albom MS; Angeles TS; Aimone LD; Haltiwanger RC; Wells-Knecht K; Ott GR; Ghose AK; Ator MA; Ruggeri B; Dorsey BD
    J Med Chem; 2012 May; 55(10):4580-93. PubMed ID: 22564207
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel 2,4-diaminopyrimidines bearing tetrahydronaphthalenyl moiety against anaplastic lymphoma kinase (ALK): Synthesis, in vitro, ex vivo, and in vivo efficacy studies.
    Song D; Lee M; Park CH; Ahn S; Yun CS; Lee CO; Kim HR; Hwang JY
    Bioorg Med Chem Lett; 2016 Apr; 26(7):1720-5. PubMed ID: 26923695
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of Brigatinib (AP26113), a Phosphine Oxide-Containing, Potent, Orally Active Inhibitor of Anaplastic Lymphoma Kinase.
    Huang WS; Liu S; Zou D; Thomas M; Wang Y; Zhou T; Romero J; Kohlmann A; Li F; Qi J; Cai L; Dwight TA; Xu Y; Xu R; Dodd R; Toms A; Parillon L; Lu X; Anjum R; Zhang S; Wang F; Keats J; Wardwell SD; Ning Y; Xu Q; Moran LE; Mohemmad QK; Jang HG; Clackson T; Narasimhan NI; Rivera VM; Zhu X; Dalgarno D; Shakespeare WC
    J Med Chem; 2016 May; 59(10):4948-64. PubMed ID: 27144831
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structure-based optimization of pyrazolo-pyrimidine and -pyridine inhibitors of PI3-kinase.
    Staben ST; Heffron TP; Sutherlin DP; Bhat SR; Castanedo GM; Chuckowree IS; Dotson J; Folkes AJ; Friedman LS; Lee L; Lesnick J; Lewis C; Murray JM; Nonomiya J; Olivero AG; Plise E; Pang J; Prior WW; Salphati L; Rouge L; Sampath D; Tsui V; Wan NC; Wang S; Weismann C; Wu P; Zhu BY
    Bioorg Med Chem Lett; 2010 Oct; 20(20):6048-51. PubMed ID: 20822905
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.